Switch to:
Also traded in: Argentina, Austria, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.33
PFE's Cash-to-Debt is ranked lower than
75% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. PFE: 0.33 )
Ranked among companies with meaningful Cash-to-Debt only.
PFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.74 Max: N/A
Current: 0.33
Equity-to-Asset 0.35
PFE's Equity-to-Asset is ranked lower than
85% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. PFE: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.47 Max: 0.66
Current: 0.35
0.35
0.66
Interest Coverage 11.44
PFE's Interest Coverage is ranked lower than
71% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. PFE: 11.44 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.27  Med: 10.39 Max: 18.94
Current: 11.44
5.27
18.94
Piotroski F-Score: 6
Altman Z-Score: 2.27
Beneish M-Score: -2.54
WACC vs ROIC
7.44%
13.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 26.42
PFE's Operating Margin % is ranked higher than
89% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. PFE: 26.42 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 14.53  Med: 23.82 Max: 29.44
Current: 26.42
14.53
29.44
Net Margin % 16.00
PFE's Net Margin % is ranked higher than
75% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. PFE: 16.00 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.67  Med: 16.8 Max: 42.65
Current: 16
12.67
42.65
ROE % 13.84
PFE's ROE % is ranked higher than
67% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. PFE: 13.84 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.29  Med: 11.86 Max: 27.93
Current: 13.84
9.29
27.93
ROA % 4.88
PFE's ROA % is ranked higher than
54% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. PFE: 4.88 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.36 Max: 12.3
Current: 4.88
4.05
12.3
ROC (Joel Greenblatt) % 67.95
PFE's ROC (Joel Greenblatt) % is ranked higher than
86% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. PFE: 67.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 40.74  Med: 57.28 Max: 82.01
Current: 67.95
40.74
82.01
3-Year Revenue Growth Rate 4.70
PFE's 3-Year Revenue Growth Rate is ranked lower than
52% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. PFE: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.5  Med: 7.3 Max: 19.2
Current: 4.7
-2.5
19.2
3-Year EBITDA Growth Rate -10.10
PFE's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. PFE: -10.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 8 Max: 36.8
Current: -10.1
-10.1
36.8
3-Year EPS without NRI Growth Rate -10.80
PFE's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. PFE: -10.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: 5.6 Max: 90.5
Current: -10.8
-26.8
90.5
GuruFocus has detected 2 Warning Signs with Pfizer Inc $PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PFE Guru Trades in Q3 2016

Jim Simons 8,566,241 sh (+390.79%)
Lee Ainslie 21,380,155 sh (+16.03%)
NWQ Managers 2,360,862 sh (+12.67%)
Ray Dalio 626,339 sh (+11.72%)
Richard Pzena 2,329,636 sh (+6.55%)
Diamond Hill Capital 11,856,263 sh (+1.80%)
Mairs and Power 4,555,073 sh (+1.62%)
Ken Fisher 31,836,368 sh (+0.35%)
David Dreman 29,962 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Eric Mindich 3,050,000 sh (unchged)
David Carlson 300,000 sh (unchged)
Ruane Cunniff Sold Out
Tom Russo Sold Out
T Rowe Price Equity Income Fund 13,875,000 sh (-0.48%)
Manning & Napier Advisors, Inc 645,026 sh (-0.92%)
Jeff Auxier 85,015 sh (-1.03%)
John Burbank 409,366 sh (-2.58%)
Ronald Muhlenkamp 36,034 sh (-2.74%)
Mario Gabelli 502,386 sh (-3.00%)
Murray Stahl 65,882 sh (-3.48%)
Barrow, Hanley, Mewhinney & Strauss 47,267,043 sh (-3.50%)
Charles Brandes 5,032,007 sh (-3.81%)
John Buckingham 72,763 sh (-3.82%)
Dodge & Cox 773,142 sh (-6.92%)
Keeley Asset Management Corp 91,630 sh (-8.92%)
Pioneer Investments 13,857,332 sh (-10.53%)
First Eagle Investment 66,061 sh (-13.15%)
Paul Tudor Jones 17,200 sh (-20.00%)
Kahn Brothers 919,757 sh (-20.50%)
Joel Greenblatt 1,158,937 sh (-40.21%)
Jeremy Grantham 6,716,818 sh (-45.31%)
John Paulson 252,000 sh (-50.63%)
» More
Q4 2016

PFE Guru Trades in Q4 2016

David Tepper 4,810,000 sh (New)
Steven Cohen 214,100 sh (New)
Eaton Vance Worldwide Health Sciences Fund 1,462,345 sh (New)
John Paulson 352,200 sh (+39.76%)
Diamond Hill Capital 12,957,027 sh (+9.28%)
Lee Ainslie 22,851,570 sh (+6.88%)
Manning & Napier Advisors, Inc 684,000 sh (+6.04%)
Murray Stahl 69,400 sh (+5.34%)
Charles Brandes 5,271,418 sh (+4.76%)
Mairs and Power 4,725,178 sh (+3.73%)
John Buckingham 74,141 sh (+1.89%)
Ken Fisher 32,204,753 sh (+1.16%)
Jeff Auxier 85,493 sh (+0.56%)
T Rowe Price Equity Income Fund 13,900,000 sh (+0.18%)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
David Carlson 300,000 sh (unchged)
John Burbank Sold Out
Mario Gabelli 490,448 sh (-2.38%)
Keeley Asset Management Corp 89,323 sh (-2.52%)
Dodge & Cox 746,972 sh (-3.38%)
NWQ Managers 2,280,229 sh (-3.42%)
Barrow, Hanley, Mewhinney & Strauss 45,401,940 sh (-3.95%)
Richard Pzena 2,217,509 sh (-4.81%)
Ronald Muhlenkamp 33,984 sh (-5.69%)
Kahn Brothers 860,290 sh (-6.47%)
Jeremy Grantham 5,451,421 sh (-18.84%)
Pioneer Investments 9,476,885 sh (-31.61%)
Joel Greenblatt 759,374 sh (-34.48%)
Paul Tudor Jones 10,900 sh (-36.63%)
David Dreman 18,901 sh (-36.92%)
Ray Dalio 282,200 sh (-54.94%)
Jim Simons 2,847,000 sh (-66.76%)
» More
Q1 2017

PFE Guru Trades in Q1 2017

George Soros 31,200 sh (New)
David Carlson 650,000 sh (+116.67%)
Joel Greenblatt 944,660 sh (+24.40%)
John Paulson 407,500 sh (+15.70%)
Charles Brandes 6,018,005 sh (+14.16%)
Manning & Napier Advisors, Inc 719,433 sh (+5.18%)
Mairs and Power 4,871,107 sh (+3.09%)
Ken Fisher 32,759,530 sh (+1.72%)
Murray Stahl 70,082 sh (+0.98%)
John Buckingham 74,585 sh (+0.60%)
David Dreman 18,901 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Richard Pzena 2,217,509 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Jeff Auxier 84,868 sh (-0.73%)
Mario Gabelli 485,466 sh (-1.02%)
Ronald Muhlenkamp 33,034 sh (-2.80%)
Diamond Hill Capital 12,358,068 sh (-4.62%)
Barrow, Hanley, Mewhinney & Strauss 42,835,523 sh (-5.65%)
Pioneer Investments 8,844,361 sh (-6.67%)
Dodge & Cox 678,070 sh (-9.22%)
T Rowe Price Equity Income Fund 12,325,000 sh (-11.33%)
Jeremy Grantham 4,786,189 sh (-12.20%)
Lee Ainslie 19,833,477 sh (-13.21%)
Kahn Brothers 667,633 sh (-22.39%)
David Tepper 3,021,000 sh (-37.19%)
Paul Tudor Jones 6,400 sh (-41.28%)
NWQ Managers 1,313,554 sh (-42.39%)
Ray Dalio 62,095 sh (-78.00%)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (-9.19%)
» More
Q2 2017

PFE Guru Trades in Q2 2017

Jim Simons 7,990,141 sh (New)
Ray Dalio 183,203 sh (+195.04%)
David Dreman 29,210 sh (+54.54%)
Manning & Napier Advisors, Inc 836,028 sh (+16.21%)
John Buckingham 82,641 sh (+10.80%)
Barrow, Hanley, Mewhinney & Strauss 46,266,431 sh (+8.01%)
Pioneer Investments 9,482,233 sh (+7.21%)
Murray Stahl 73,976 sh (+5.56%)
Richard Pzena 2,332,274 sh (+5.18%)
Ken Fisher 34,035,362 sh (+3.89%)
Jeff Auxier 85,668 sh (+0.94%)
David Carlson 650,000 sh (unchged)
First Eagle Investment 66,061 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
Ronald Muhlenkamp 33,034 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (unchged)
Paul Tudor Jones Sold Out
David Tepper Sold Out
George Soros Sold Out
John Paulson Sold Out
Mairs and Power 4,868,827 sh (-0.05%)
Jeremy Grantham 4,783,377 sh (-0.06%)
Mario Gabelli 484,359 sh (-0.23%)
NWQ Managers 1,262,358 sh (-3.90%)
Diamond Hill Capital 11,331,723 sh (-8.31%)
Kahn Brothers 577,616 sh (-13.48%)
Charles Brandes 5,134,710 sh (-14.68%)
Dodge & Cox 575,228 sh (-15.17%)
T Rowe Price Equity Income Fund 10,237,000 sh (-16.94%)
Lee Ainslie 10,052,571 sh (-49.32%)
Joel Greenblatt 470,928 sh (-50.15%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Add 8.01%0.18%$31.75 - $34.34 $ 32.67-2%46,266,431
Ken Fisher 2017-06-30 Add 3.89%0.07%$31.75 - $34.34 $ 32.67-2%34,035,362
T Rowe Price Equity Income Fund 2017-06-30 Reduce -16.94%0.33%$31.75 - $34.34 $ 32.67-2%10,237,000
Charles Brandes 2017-06-30 Reduce -14.68%0.45%$31.75 - $34.34 $ 32.67-2%5,134,710
Richard Pzena 2017-06-30 Add 5.18%0.02%$31.75 - $34.34 $ 32.67-2%2,332,274
NWQ Managers 2017-06-30 Reduce -3.90%0.02%$31.75 - $34.34 $ 32.67-2%1,262,358
Kahn Brothers 2017-06-30 Reduce -13.48%0.53%$31.75 - $34.34 $ 32.67-2%577,616
Dodge & Cox 2017-06-30 Reduce -15.17%$31.75 - $34.34 $ 32.67-2%575,228
Mario Gabelli 2017-06-30 Reduce -0.23%$31.75 - $34.34 $ 32.67-2%484,359
Joel Greenblatt 2017-06-30 Reduce -50.15%0.21%$31.75 - $34.34 $ 32.67-2%470,928
David Dreman 2017-06-30 Add 54.54%0.19%$31.75 - $34.34 $ 32.67-2%29,210
George Soros 2017-06-30 Sold Out 0.03%$31.75 - $34.34 $ 32.67-2%0
David Tepper 2017-06-30 Sold Out 1.7%$31.75 - $34.34 $ 32.67-2%0
John Paulson 2017-06-30 Sold Out 0.19%$31.75 - $34.34 $ 32.67-2%0
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -5.65%0.12%$31.15 - $34.63 $ 32.67-2%42,835,523
Ken Fisher 2017-03-31 Add 1.72%0.03%$31.15 - $34.63 $ 32.67-2%32,759,530
T Rowe Price Equity Income Fund 2017-03-31 Reduce -11.33%0.23%$31.15 - $34.63 $ 32.67-2%12,325,000
Charles Brandes 2017-03-31 Add 14.16%0.38%$31.15 - $34.63 $ 32.67-2%6,018,005
David Tepper 2017-03-31 Reduce -37.19%1.03%$31.15 - $34.63 $ 32.67-2%3,021,000
NWQ Managers 2017-03-31 Reduce -42.39%0.43%$31.15 - $34.63 $ 32.67-2%1,313,554
Joel Greenblatt 2017-03-31 Add 24.40%0.08%$31.15 - $34.63 $ 32.67-2%944,660
Dodge & Cox 2017-03-31 Reduce -9.22%$31.15 - $34.63 $ 32.67-2%678,070
Kahn Brothers 2017-03-31 Reduce -22.39%1.06%$31.15 - $34.63 $ 32.67-2%667,633
Mario Gabelli 2017-03-31 Reduce -1.02%$31.15 - $34.63 $ 32.67-2%485,466
John Paulson 2017-03-31 Add 15.70%0.03%$31.15 - $34.63 $ 32.67-2%407,500
Ronald Muhlenkamp 2017-03-31 Reduce -2.80%0.01%$31.15 - $34.63 $ 32.67-2%33,034
George Soros 2017-03-31 New Buy0.03%$31.15 - $34.63 $ 32.67-2%31,200
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Reduce -3.95%0.1%$29.89 - $33.9 $ 32.672%45,401,940
Ken Fisher 2016-12-31 Add 1.16%0.02%$29.89 - $33.9 $ 32.672%32,204,753
T Rowe Price Equity Income Fund 2016-12-31 Add 0.18%$29.89 - $33.9 $ 32.672%13,900,000
Charles Brandes 2016-12-31 Add 4.76%0.12%$29.89 - $33.9 $ 32.672%5,271,418
David Tepper 2016-12-31 New Buy2.77%$29.89 - $33.9 $ 32.672%4,810,000
NWQ Managers 2016-12-31 Reduce -3.42%0.04%$29.89 - $33.9 $ 32.672%2,280,229
Richard Pzena 2016-12-31 Reduce -4.81%0.02%$29.89 - $33.9 $ 32.672%2,217,509
Kahn Brothers 2016-12-31 Reduce -6.47%0.36%$29.89 - $33.9 $ 32.672%860,290
Joel Greenblatt 2016-12-31 Reduce -34.48%0.18%$29.89 - $33.9 $ 32.672%759,374
Dodge & Cox 2016-12-31 Reduce -3.38%$29.89 - $33.9 $ 32.672%746,972
Mario Gabelli 2016-12-31 Reduce -2.38%$29.89 - $33.9 $ 32.672%490,448
John Paulson 2016-12-31 Add 39.76%0.04%$29.89 - $33.9 $ 32.672%352,200
Keeley Asset Management Corp 2016-12-31 Reduce -2.52%$29.89 - $33.9 $ 32.672%89,323
Ronald Muhlenkamp 2016-12-31 Reduce -5.69%0.03%$29.89 - $33.9 $ 32.672%33,984
David Dreman 2016-12-31 Reduce -36.92%0.23%$29.89 - $33.9 $ 32.672%18,901
Barrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce -3.50%0.09%$33.32 - $37.31 $ 32.67-7%47,267,043
Ken Fisher 2016-09-30 Add 0.35%0.01%$33.32 - $37.31 $ 32.67-7%31,836,368
T Rowe Price Equity Income Fund 2016-09-30 Reduce -0.48%0.01%$33.32 - $37.31 $ 32.67-7%13,875,000
Charles Brandes 2016-09-30 Reduce -3.81%0.11%$33.32 - $37.31 $ 32.67-7%5,032,007
NWQ Managers 2016-09-30 Add 12.67%0.13%$33.32 - $37.31 $ 32.67-7%2,360,862
Richard Pzena 2016-09-30 Add 6.55%0.03%$33.32 - $37.31 $ 32.67-7%2,329,636
Joel Greenblatt 2016-09-30 Reduce -40.21%0.33%$33.32 - $37.31 $ 32.67-7%1,158,937
Kahn Brothers 2016-09-30 Reduce -20.50%1.62%$33.32 - $37.31 $ 32.67-7%919,757
Dodge & Cox 2016-09-30 Reduce -6.92%$33.32 - $37.31 $ 32.67-7%773,142
Mario Gabelli 2016-09-30 Reduce -3.00%$33.32 - $37.31 $ 32.67-7%502,386
John Paulson 2016-09-30 Reduce -50.63%0.1%$33.32 - $37.31 $ 32.67-7%252,000
Keeley Asset Management Corp 2016-09-30 Reduce -8.92%0.01%$33.32 - $37.31 $ 32.67-7%91,630
First Eagle Investment 2016-09-30 Reduce -13.15%$33.32 - $37.31 $ 32.67-7%66,061
Ronald Muhlenkamp 2016-09-30 Reduce -2.74%0.01%$33.32 - $37.31 $ 32.67-7%36,034
Ruane Cunniff 2016-09-30 Sold Out $33.32 - $37.31 $ 32.67-7%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:MRK, NYSE:ABBV, NYSE:BMY, NYSE:LLY, NYSE:JNJ, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:RMTI, NAS:ZGNX, NAS:ALIM, AMEX:NNVC, NAS:PRPH, AMEX:AXN, NAS:TNXP, OTCPK:INNV, NAS:ALQA, NAS:IMNP, OTCPK:INBP, OTCPK:ENZB » details
Traded in other countries:PFE.Argentina, PFE.Austria, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, 0Q1N.UK,
Headquarter Location:USA
Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing over 50% of its total sales.

Guru Investment Theses on Pfizer Inc

Gabelli Funds Comments on Pfizer Inc. - Aug 04, 2016

Pfizer Inc. (NYSE:PFE) (3.8%) (PFE – $29.64 – NYSE), headquartered in New York City, is one of the world’s largest research based pharmaceutical companies, with sales of $48.9 billion in 2015. The company’s drugs include the blockbusters Enbrel for autoimmune diseases, Lipitor for high cholesterol, Lyrica for pain, and Viagra for erectile dysfunction. The company’s late-stage pipeline includes drugs being developed to treat cancer, cardiovascular disease, and inflammatory conditions. Pfizer also offers consumer healthcare products, including Advil, Centrum, ChapStick, Emergen-C, and Robitussin. In April 2016, the company terminated its planned acquisition of Allergan plc following unfavorable tax regulations from the U.S. Treasury. Pfizer is now considering whether to split the company into two segments, one for high growth innovative pharmaceuticals and one for lower growth/declining established pharmaceuticals, with a decision expected by the end of 2016.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Pfizer Inc

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE
Dow Jones Reaches Another New High, Closes at 22,026.10 Large-cap stocks mostly lower on Thursday
U.S. market indexes were mixed on Thursday. For the day, the Dow Jones Industrial Average closed at 22,026.10 for a gain of 9.86 points or 0.04%. The S&P 500 closed at 2,472.16 for a loss of -5.41 points or -0.22%. The Nasdaq Composite closed at 6,340.34 for a loss of -22.30 points or -0.35%. The VIX Volatility Index was higher at 10.36 for a gain of 0.08 points or 0.78%. Read more...
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...
Stock Markets Mostly Flat Tuesday Morning Investors are waiting for several speeches by Fed officials
At a time when the three indices are down and Asian stocks rise as the dollar reached a two-month peak against the yen. The U.S. dollar index, which follows a basket of six currencies, is at 96.08. Meanwhile, a senior Federal Reserve official expects a further increase in interest rates and the central bank will begin to lower its huge balance in the coming months. Read more...
Wall Street Opens Without a Clear Direction The market expects more economic data and the appearance of Yellen before Congress
In a volatile morning session, the three major indices are now in the green while the U.S. economy continues to generate jobs and growth at a steady pace, with good data on consumer confidence and investment according to the Federal Reserve's semi-annual report. Although there are few indications of a liquidity crisis in the fixed-income market, there are not any problems with valuations of financial assets. Notwithstanding, the Fed highlighted some long-term problems stemming from weak productivity growth. Read more...
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas that offer returns of 18% or more!
Nasdaq Reports Another New High Dow Jones and S&P 500 report losses for the day
U.S. market indexes were mixed on Tuesday with the Nasdaq reporting another new high. Read more...

Ratios

vs
industry
vs
history
PE Ratio 23.85
PFE's PE Ratio is ranked lower than
51% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. PFE: 23.85 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 16.55 Max: 34.77
Current: 23.85
7.68
34.77
Forward PE Ratio 12.84
PFE's Forward PE Ratio is ranked higher than
78% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. PFE: 12.84 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 23.67
PFE's PE Ratio without NRI is ranked lower than
51% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. PFE: 23.67 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.83  Med: 19.43 Max: 34.43
Current: 23.67
9.83
34.43
Price-to-Owner-Earnings 15.98
PFE's Price-to-Owner-Earnings is ranked higher than
75% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. PFE: 15.98 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.44  Med: 10.89 Max: 36.49
Current: 15.98
5.44
36.49
PB Ratio 3.34
PFE's PB Ratio is ranked lower than
59% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. PFE: 3.34 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.44 Max: 3.72
Current: 3.34
1.32
3.72
PS Ratio 3.81
PFE's PS Ratio is ranked lower than
60% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. PFE: 3.81 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.63 Max: 4.74
Current: 3.81
1.72
4.74
Price-to-Free-Cash-Flow 14.84
PFE's Price-to-Free-Cash-Flow is ranked higher than
73% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. PFE: 14.84 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 13.15 Max: 18.91
Current: 14.84
5.02
18.91
Price-to-Operating-Cash-Flow 12.87
PFE's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. PFE: 12.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 11.78 Max: 15.89
Current: 12.87
4.55
15.89
EV-to-EBIT 19.73
PFE's EV-to-EBIT is ranked lower than
57% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. PFE: 19.73 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.5 Max: 28.8
Current: 19.73
6.7
28.8
EV-to-EBITDA 12.85
PFE's EV-to-EBITDA is ranked higher than
58% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. PFE: 12.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.3 Max: 17.3
Current: 12.85
4.9
17.3
Shiller PE Ratio 20.24
PFE's Shiller PE Ratio is ranked higher than
79% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. PFE: 20.24 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.12  Med: 16.73 Max: 25.32
Current: 20.24
9.12
25.32
Current Ratio 1.34
PFE's Current Ratio is ranked lower than
74% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. PFE: 1.34 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.53 Max: 3.18
Current: 1.34
0.98
3.18
Quick Ratio 1.06
PFE's Quick Ratio is ranked lower than
71% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. PFE: 1.06 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.23 Max: 2.86
Current: 1.06
0.74
2.86
Days Inventory 235.56
PFE's Days Inventory is ranked lower than
86% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. PFE: 235.56 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 185.33  Med: 229.24 Max: 344.63
Current: 235.56
185.33
344.63
Days Sales Outstanding 66.07
PFE's Days Sales Outstanding is ranked higher than
62% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. PFE: 66.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 69.5 Max: 106.89
Current: 66.07
56.83
106.89
Days Payable 109.76
PFE's Days Payable is ranked higher than
70% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. PFE: 109.76 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 115.45 Max: 179.46
Current: 109.76
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.86
PFE's Dividend Yield % is ranked higher than
89% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. PFE: 3.86 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.7 Max: 10.4
Current: 3.86
2.9
10.4
Dividend Payout Ratio 0.91
PFE's Dividend Payout Ratio is ranked lower than
77% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. PFE: 0.91 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.77 Max: 1.08
Current: 0.91
0.58
1.08
3-Year Dividend Growth Rate 7.70
PFE's 3-Year Dividend Growth Rate is ranked higher than
53% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. PFE: 7.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.6 Max: 22.6
Current: 7.7
-14.7
22.6
Forward Dividend Yield % 3.92
PFE's Forward Dividend Yield % is ranked higher than
88% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. PFE: 3.92 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.75
PFE's 5-Year Yield-on-Cost % is ranked higher than
89% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. PFE: 5.75 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.34  Med: 5.54 Max: 15.57
Current: 5.75
4.34
15.57
3-Year Average Share Buyback Ratio 1.70
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. PFE: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: 0.1 Max: 7.2
Current: 1.7
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.07
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. PFE: 1.07 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.42 Max: 9.98
Current: 1.07
0.53
9.98
Price-to-Median-PS-Value 1.05
PFE's Price-to-Median-PS-Value is ranked higher than
50% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. PFE: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 1.05 Max: 3.28
Current: 1.05
0.43
3.28
Earnings Yield (Greenblatt) % 5.07
PFE's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. PFE: 5.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.5  Med: 6.9 Max: 14.9
Current: 5.07
3.5
14.9
Forward Rate of Return (Yacktman) % 2.83
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. PFE: 2.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.5  Med: 12.4 Max: 23.3
Current: 2.83
2.5
23.3

More Statistics

Revenue (TTM) (Mil) $52,348.00
EPS (TTM) $ 1.37
Beta1.05
Short Percentage of Float0.73%
52-Week Range $29.83 - 35.38
Shares Outstanding (Mil)5,947.35

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 52,816 54,004 53,235
EPS ($) 2.54 2.73 2.78
EPS without NRI ($) 2.54 2.73 2.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.50%
Dividends per Share ($) 1.29 1.37 1.45
» More Articles for PFE

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PF Aug 10 2017 
Dow Jones Reaches Another New High, Closes at 22,026.10 Aug 04 2017 
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinom Jul 21 2017 
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma Jul 14 2017 
Stock Markets Mostly Flat Tuesday Morning Jul 11 2017 
Wall Street Opens Without a Clear Direction Jul 10 2017 
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of en Jun 09 2017 
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Recei Jun 07 2017 
Portola Pharmaceuticals Could Be a Great June Trade Jun 02 2017 
Investors: Option reports for Citigroup, The Gap, Nike, NVIDIA and Pfizer Inc. include trade ideas t May 22 2017 

More From Other Websites
Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant Aug 20 2017
Here's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now Aug 20 2017
[$$] Healthy Dividends Aug 19 2017
The FDA Just Approved a New Pfizer Cancer Drug for a Rare, Vicious Leukemia Aug 18 2017
Pfizer's (PFE) Besponsa Gets FDA Nod with a Boxed Warning Aug 18 2017
See what the IHS Markit Score report has to say about Pfizer Inc. Aug 18 2017
The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk Aug 18 2017
Analysts’ Recommendations for Bristol-Myers Squibb in August 2017 Aug 18 2017
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo Aug 18 2017
Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by... Aug 18 2017
Top Analyst Reports for Pfizer, TJX Companies & Honda Aug 17 2017
FDA OKs Pfizer drug for rare, fast-killing type of leukemia Aug 17 2017
FDA approves Pfizer's drug for rare blood cancer Aug 17 2017
Pfizer Receives U.S. FDA Approval for BESPONSA® (inotuzumab ozogamicin) Aug 17 2017
Can Pfizer Bank on New Immunotherapy Bavencio for Growth? Aug 17 2017
How Amgen’s Nephrology Drugs Are Positioned after 2Q17? Aug 17 2017
The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak Aug 16 2017
Pfizer’s Corporate and Pipeline Developments in 2Q17 Aug 15 2017
Pfizer Inc. breached its 50 day moving average in a Bullish Manner : PFE-US : August 15, 2017 Aug 15 2017
Pfizer’s Important Product Developments in 2Q17 Aug 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}